Sanofis advanced diabetes therapy, Toujeo, approved by Kuwait Ministry of Health
The control of blood sugar level levels in patients with diabetes stays sub-optimal, with 1 in 2 patients on treatment for diabetes not reaching their glycemic objectives. With the aim of resolving this unmet requirement of patients, Sanofi, under the patronage of Kuwait Diabetes Society, introduced Toujeo (insulin glargine U300), a next generation basal insulin, to enhance the control of blood sugar in adults living with type 1 and type 2 diabetes.
In alignment with the on-going efforts in Kuwait to improve diabetes management, the introduction of Toujeo will assist enhance treatment outcome and provide much better treatment alternatives for some people with diabetes.
"With the rising occurrence of diabetes in the nation, our venture is to embrace every measure towards making sure reliable diabetes control for our clients. The launch of the brand-new therapy is a favorable addition to our existing diabetes treatment portfolio. Together with Sanofi, we are pleased to be the very first country in the Middle East making this offered to our clients," said Dr. Hessa Al Kandari, President of Kuwait Diabetes Society.
Talking about the challenges faced by patients, Dr. Waleed Al-Dahi, Consultant Endocrinologist & Diabetes, Mubarak Al-Kabeer Hospital, stated, "Hypoglycemia is one of the crucial worrying adverse effects for people with diabetes. It triggers patients to decrease their insulin doses, resulting in irregular blood sugar level levels. In addition, the concern over hypoglycemia causes clients to eat at differing hours and in larger quantities causing weight gain.".
Toujeo offers stable control that lasts a complete 24 hours and beyond, v.It likewise provides the benefits of dosage flexibility (up to 3 hours) when needed and deals with the issue of insulin-related body weight gain. The new therapy has a neutral impact on cardiovascular conditions, making sure long-lasting safety for clients with co-morbidities v, vi.
"Sanofi is proud of its leadership and long heritage in diabetes and insulin therapies, consisting of Lantus which has supported patients in the management of their diabetes for more than a years. We are committed to bringing innovative therapies that intend to provide much better health results for individuals with diabetes in Kuwait. With the introduction of Toujeo , we provide reliable option that will resolve some of the previously unmet needs of diabetes clients in the country," stated Jean-Paul Scheuer, Country Chair and General Manager, Rx for Sanofi Gulf.
Toujeo has received approval from a lot of international health authorities, consisting of the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) vii, in addition to the Kuwait Ministry of Health. The approvals were based upon a series of medical trials (EDITION) that were conducted on over 3500 clients, and which results proved positive and effective .
